GLP-1 Microdosing: Exploring Longevity Beyond Weight Loss

A burgeoning community of individuals is actively exploring the potential anti-aging and healthspan benefits of GLP-1 receptor agonists, powerful medications such as Ozempic and Wegovy. These experimenters are intentionally utilizing significantly reduced dosages, often much lower than those clinically prescribed for diabetes management or weight loss. Their objective is to tap into the drugs’ broader metabolic and cellular effects, hoping to unlock pathways to extended lifespan and improved overall well-being, venturing into territory beyond the conventionally studied applications of these potent compounds.